The board of directors of UMP Healthcare Holdings Limited announced that Dr. LEE Kar Chung, Felix, an executive Director will be re-designated as a non-executive Director with effect from 24 November 2023. Dr. LEE, aged 42, is currently a Senior Vice President of Chow Tai Fook Enterprises Limited (CTFE) with responsibilities in making investments in the healthcare sector in Asia and globally and a director of Healthcare Ventures Holdings Limited, a wholly owned subsidiary of CTFE. Dr. LEE is also an independent non-executive director of Asymchem Laboratories (Tianjin) Co.

Ltd. and a non-executive director of ClouDr Group Limited. Dr. LEE is also a director of various companies of the Group. He has nearly 20 years of experience in healthcare, law and finance.

He was an associate with the law firm Freshfields Bruckhaus Deringer before he left in February 2008 to join UBS AG, Hong Kong branch as an analyst in the investment banking department until January 2009. He then joined the investment banking department of Deutsche Bank AG, Hong Kong branch and last held the position of director in the Corporate Advisory Group, where he worked from January 2009 to August 2014. From August 2015 to June 2023, Dr. LEE was an independent non-executive director of China Resources Medical Holdings Company Limited.

Dr. LEE is also a Vice Chairman of the China Committee, the Hong Kong General Chamber of Commerce. Dr. LEE obtained a Bachelor of Laws degree from the London School of Economics and Political Sciences and a Postgraduate Certificate in Laws from the University of Hong Kong in July 2003 and June 2004, respectively. He obtained a Doctor of Business Administration from the University of Wales Trinity Saint David in 2023.

He is a solicitor of the High Court of Hong Kong since September 2007 and a solicitor (non-practising) in the Senior Courts of England and Wales since February 2013. Following his re-designation, Dr. LEE will enter into a new letter of appointment with the Company as a non-executive Director for a fixed term of one year commencing from the date of his re-designation subject to retirement by rotation in accordance with the articles of association of the Company. The Board announced that Dr. LEE Kar Chung, Felix will cease to act as the authorised representative of the Company for accepting service of process or notice in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and the authorised representative of the Company under Rule 3.05 of the Listing Rules (the Exchange Authorised Representative) all with effect from 24 November 2023.

Accordingly, Ms. KWOK Cheuk Kwan, Jacquen will be appointed as the Exchange Authorised Representative and the Part 16 Authorised Representative all with effect from 24 November 2023.